OOIR: Observatory of International Research

Papers

(The TQCC of mAbs is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Correction	306
Characterization of anti-SARS-CoV-2 monoclonal antibodies focusing on antigen binding, neutralization, and FcγR activation via formation of immune complex	245
Biologics developability data analysis using hierarchical clustering accelerates candidate lead selection, optimization, and preformulation screening	163
CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma	137
Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties	134
In silico prediction of post-translational modifications in therapeutic antibodies	103
A next-generation Fab library platform directly yielding drug-like antibodies with high affinity, diversity, and developability	103
Development of a novel, high-throughput imaged capillary isoelectric focusing-Western method to characterize charge heterogeneity of monoclonal antibody heavy and light chains	102
Insight into the avidity–affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn	79
Seq2scFv: a toolkit for the comprehensive analysis of display libraries from long-read sequencing platforms	79
A window into the human immune system: comprehensive characterization of the complexity of antibody complementary-determining regions in functional antibodies	77
Mechanistic and predictive formulation development for viscosity mitigation of high-concentration biotherapeutics	73
Correction	72
An antibody developability triaging pipeline exploiting protein language models	71
Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies	70
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis	68
Selection of target-binding proteins from the information of weakly enriched phage display libraries by deep sequencing and machine learning	68
Correction	58
Structural and functional characterization of a monoclonal antibody blocking TIGIT	57
Mitochondrial membrane potential-enriched CHO host: a novel and powerful tool for improving biomanufacturing capability	53
Antibodies to watch in 2024	51
A mouse pancreatic organoid model to compare PD-L1 blocking antibodies	48
Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products	47
The proximity of the N- and C- termini of bovine knob domains enable engineering of target specificity into polypeptide chains	43
The nonglycosylated variant in therapeutic monoclonal antibodies preferentially forms large aggregates under typical thermal stresses used in forced degradation studies	41

GlycoVHH: optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery	41
Predicting antibody binders and generating synthetic antibodies using deep learning	41
Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs	41
Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBs	40
Rapid expression of therapeutic antibodies in mammalian cells via mRNA transfection	39
A highly selective TCR-mimic antibody reveals unexpected mechanisms of HBV peptide-MHC recognition and previously unknown target biology	39
Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies	38
In-line product quality monitoring during biopharmaceutical manufacturing using computational Raman spectroscopy	36
Unambiguous identification of α-Gal epitopes in intact monoclonal antibodies by NMR spectroscopy	35
Breaking barriers in antibody discovery: harnessing divergent species for accessing difficult and conserved drug targets	34
The emergence of cell-based protein arrays to test for polyspecific off-target binding of antibody therapeutics	34
Impact of IgG subclass on monoclonal antibody developability	34
Identification of tyrosine sulfation in the variable region of a bispecific antibody and its effect on stability and biological activity	33
Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19	29
Decoding the mannose receptor-mAb interaction: the importance of high-mannose N-glycans and glycan-pairing	29
Variable domain mutational analysis to probe the molecular mechanisms of high viscosity of an IgG ₁ antibody	29
Epitope mapping of anti-drug antibodies to a clinical candidate bispecific antibody	28
Separating clinical antibodies from repertoire antibodies, a path to in silico developability assessment	28
Physiochemical and functional evaluation of the first-in-class anti-cancer IgE antibody drug, MOv18, through process development and good manufacturing practice production	28
T cell margination: investigating the detour of T cells following forimtamig treatment in humanized mice	27
Temperature and excipient mediated modulation of monoclonal antibody interactions revealed by k D, rheology, and Raman spectroscopy	26
Quantifying antibody binding: techniques and therapeutic implications	26
Discovery of broadly neutralizing V _H Hs against short-chain α-neurotoxins using a consensus toxin as an antigen	25
Targeted protein degradation through site-specific antibody conjugation with mannose 6-phosphate glycan	25
Higher order receptor clustering due to the IgG3 subclass is necessary for TLR4 signaling and tolerance induction by novel human anti-TLR4 antibodies	25
Sequence-based engineering of pH-sensitive antibodies for tumor targeting or endosomal recycling applications	24
In silico proof of principle of machine learning-based antibody design at unconstrained scale	24
Comprehensive characterization of higher order structure changes in methionine oxidized monoclonal antibodies via NMR chemometric analysis and biophysical approaches	22
Building a potent TREM2 agonistic, biparatopic, common light chain antibody	22
Bivalent non-human gal-α1-3-gal glycan epitopes in the Fc region of a monoclonal antibody model can be recognized by anti-Gal-α1-3-Gal IgE antibodies	22
Analytical development and application of a targeted liquid chromatography-tandem mass spectrometry assay for chimeric aducanumab	22
Balancing brain exposure, pharmacokinetics and safety of transferrin receptor antibodies for delivery of neuro-therapeutics	22
Modifying antibody-FcRn interactions to increase the transport of antibodies through the blood-brain barrier	21
The eIg technology to generate Ig-like bispecific antibodies	21
Rapid affinity-based purification of multi-specific antibodies using Kappa Select and Protein L	21
Cost and supply considerations for antibody therapeutics	21
Evolution of phage display libraries for therapeutic antibody discovery	21
Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies	21
A versatile design platform for glycoengineering therapeutic antibodies	20
Electrostatic properties of human germlines and biodistribution of small biologics	20
Deciphering deamidation and isomerization in therapeutic proteins: Effect of neighboring residue	20
Improving the integrity and reproducibility of research that uses antibodies: a technical, data sharing, behavioral and policy challenge	19
A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations	19
Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics	19
Hybrid IgE-IgG1 antibodies (IgEG): a new antibody class that combines IgE and IgG functionality	19
IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation	19
A glyco-engineering approach for site-specific conjugation to Fab glycans	19
Antigenic landscapes on Staphylococcus aureus pore-forming toxins reveal insights into specificity and cross-neutralization	19
RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties	19
Efficient production of bispecific antibody by FAST-Ig ^TM and its application to NXT007 for the treatment of hemophilia A	18

Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework	18
Humatch - fast, gene-specific joint humanisation of antibody heavy and light chains	18
A comprehensive strategy for pandemic preparedness with neutralizing monoclonal antibodies	18
Engineering death resistance in CHO cells for improved perfusion culture	18
Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity	17
Structural and biochemical differences between non-catalytic and catalytic antibodies	17
Translational minimal physiologically based pharmacokinetic model for transferrin receptor-mediated brain delivery of antibodies	17
Leveraging multi-modal feature learning for predictions of antibody viscosity	17
International nonproprietary names for monoclonal antibodies: an evolving nomenclature system	17
Toward generalizable prediction of antibody thermostability using machine learning on sequence and structure features	17
Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG ₁ antibodies	17
Reduction of monoclonal antibody viscosity using interpretable machine learning	17
Non-targeted characterization of attributes affecting antibody-FcγRIIIa V158 (CD16a) binding via online affinity chromatography-mass spectrometry	16
Therapeutic efficacy of a potent anti-Venezuelan equine encephalitis virus antibody is contingent on Fc effector function	16
Predicting purification process fit of monoclonal antibodies using machine learning	16
Development of a PRAME pMHC targeted T cell engager for solid tumor therapy	16
Coactivation of Tie2 and Wnt signaling using an antibody–R-spondin fusion potentiates therapeutic angiogenesis and vessel stabilization in hindlimb ischemia	16
Predicting the clinical subcutaneous absorption rate constant of monoclonal antibodies using only the primary sequence: a machine learning approach	16
Discovery and characterization of two anti-PD-1 antibodies with a unique binding mechanism to human PD-1	16
Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows	16
With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development process	15
A novel anti-NGF PEGylated Fab’ provides analgesia with lower risk of adverse effects	15
Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1	15
Understanding the structure–property relationship of bispecific monoclonal antibodies with Fc site-specific substitutions	15
Combining deep mutational scanning and SPR binning approaches for large-scale epitope identification of anti-ricin antibodies	15
Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?	15
Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers	15
Full-length recombinant antibodies from Escherichia coli : production, characterization, effector function (Fc) engineering, and clinical evaluation	15
Antibody markup language (AbML) — a notation language for antibody-based drug formats and software for creating and rendering AbML (abYdraw)	15
A machine learning strategy for the identification of key in silico descriptors and prediction models for IgG monoclonal antibody developability properties	15